FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2285667067> ?p ?o ?g. }

• W2285667067 endingPage "4023" @default.
• W2285667067 startingPage "4009" @default.
• W2285667067 abstract "// Rosanna Sestito 1, * , Roberta Cianfrocca 1, * , Laura Rosanò 1 , Piera Tocci 1 , Elisa Semprucci 1 , Valeriana Di Castro 1 , Valentina Caprara 1 , Gabriella Ferrandina 2 , Andrea Sacconi 3 , Giovanni Blandino 3 , Anna Bagnato 1 1 Translational Research Functional Departmental Area, Regina Elena National Cancer Institute, Rome, Italy 2 Gynecologic Oncology Unit, Catholic University of Rome, Rome, Italy 3 Translational Oncogenomic Unit, Regina Elena National Cancer Institute, Rome, Italy * These authors have contributed equally to this work Correspondence to: Anna Bagnato, e-mail: bagnato@ifo.it Keywords: ovarian carcinoma, endothelin A receptor, miR-30a, chemoresistance, endothelin-1 Received: September 01, 2015      Accepted: November 24, 2015      Published: December 10, 2015 ABSTRACT Drug resistance remains the major clinical barrier to successful treatment in epithelial ovarian carcinoma (EOC) patients, and the evidence of microRNA involvement in drug resistance has been recently emerging. Endothelin-1 (ET-1)/ET A receptor (ET A R) axis is aberrantly activated in chemoresistant EOC cells and elicits pleiotropic effects promoting epithelial-to-mesenchymal transition (EMT) and the acquisition of chemoresistance. However, the relationship between ET A R and miRNA is still unknown. Hence, in this study we evaluated whether dysregulation of miRNA might enhance ET A R expression in sensitive and resistant EOC cells. Based on bioinformatic tools, we selected putative miRNA able to recognize the 3′UTR of ET A R. An inverse correlation was observed between the expression levels of miR-30a and ET A R in both EOC cell lines and tumor samples. miR-30a was found to specifically bind to the 3′UTR of ET A R mRNA, indicating that ET A R is a direct target of miR-30a. Overexpression of miR-30a decreased Akt and mitogen activated protein kinase signaling pathway activation, cell proliferation, invasion, plasticity, EMT marker levels, and vascular endothelial growth factor release. Interestingly, ectopic expression of miR-30a re-sensitized platinum-resistant EOC cells to cisplatinum-induced apoptosis. Consistently, resistant EOC xenografts overexpressing miR-30a resulted in significantly less tumor growth than controls. Together our study provides a new perspective on the regulatory mechanism of ET A R gene. Interestingly, our findings highlight that blockade of ET A R regulatory axis is the mechanism underlying the tumor suppressor function of miR-30a in chemoresistant EOC cells." @default.
• W2285667067 created "2016-06-24" @default.
• W2285667067 creator A5017244417 @default.
• W2285667067 creator A5019259641 @default.
• W2285667067 creator A5030229940 @default.
• W2285667067 creator A5039844504 @default.
• W2285667067 creator A5045749901 @default.
• W2285667067 creator A5047759445 @default.
• W2285667067 creator A5056920830 @default.
• W2285667067 creator A5066311500 @default.
• W2285667067 creator A5069165102 @default.
• W2285667067 creator A5075841774 @default.
• W2285667067 creator A5090987336 @default.
• W2285667067 date "2015-12-10" @default.
• W2285667067 modified "2023-10-02" @default.
• W2285667067 title "miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma" @default.
• W2285667067 cites W1229827077 @default.
• W2285667067 cites W1695398347 @default.
• W2285667067 cites W1966347977 @default.
• W2285667067 cites W1975365605 @default.
• W2285667067 cites W1990653694 @default.
• W2285667067 cites W1992642151 @default.
• W2285667067 cites W1994061059 @default.
• W2285667067 cites W1995351570 @default.
• W2285667067 cites W2001574956 @default.
• W2285667067 cites W2020359290 @default.
• W2285667067 cites W2029922807 @default.
• W2285667067 cites W2038843789 @default.
• W2285667067 cites W2040191060 @default.
• W2285667067 cites W2041229150 @default.
• W2285667067 cites W2045755466 @default.
• W2285667067 cites W2045842462 @default.
• W2285667067 cites W2047101312 @default.
• W2285667067 cites W2055720287 @default.
• W2285667067 cites W2058916559 @default.
• W2285667067 cites W2066199622 @default.
• W2285667067 cites W2083381199 @default.
• W2285667067 cites W2090736171 @default.
• W2285667067 cites W2093241325 @default.
• W2285667067 cites W2105381419 @default.
• W2285667067 cites W2106067112 @default.
• W2285667067 cites W2109449896 @default.
• W2285667067 cites W2114570899 @default.
• W2285667067 cites W2119017522 @default.
• W2285667067 cites W2120732885 @default.
• W2285667067 cites W2123113463 @default.
• W2285667067 cites W2123696077 @default.
• W2285667067 cites W2140346107 @default.
• W2285667067 cites W2148946562 @default.
• W2285667067 cites W2153054028 @default.
• W2285667067 cites W2159841830 @default.
• W2285667067 cites W2161149887 @default.
• W2285667067 cites W2162674813 @default.
• W2285667067 cites W2163025807 @default.
• W2285667067 cites W2165948908 @default.
• W2285667067 cites W2166240615 @default.
• W2285667067 cites W4210738594 @default.
• W2285667067 cites W4237473415 @default.
• W2285667067 cites W4293241248 @default.
• W2285667067 doi "https://doi.org/10.18632/oncotarget.6546" @default.
• W2285667067 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4826186" @default.
• W2285667067 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26675258" @default.
• W2285667067 hasPublicationYear "2015" @default.
• W2285667067 type Work @default.
• W2285667067 sameAs 2285667067 @default.
• W2285667067 citedByCount "42" @default.
• W2285667067 countsByYear W22856670672016 @default.
• W2285667067 countsByYear W22856670672017 @default.
• W2285667067 countsByYear W22856670672018 @default.
• W2285667067 countsByYear W22856670672019 @default.
• W2285667067 countsByYear W22856670672020 @default.
• W2285667067 countsByYear W22856670672021 @default.
• W2285667067 countsByYear W22856670672022 @default.
• W2285667067 crossrefType "journal-article" @default.
• W2285667067 hasAuthorship W2285667067A5017244417 @default.
• W2285667067 hasAuthorship W2285667067A5019259641 @default.
• W2285667067 hasAuthorship W2285667067A5030229940 @default.
• W2285667067 hasAuthorship W2285667067A5039844504 @default.
• W2285667067 hasAuthorship W2285667067A5045749901 @default.
• W2285667067 hasAuthorship W2285667067A5047759445 @default.
• W2285667067 hasAuthorship W2285667067A5056920830 @default.
• W2285667067 hasAuthorship W2285667067A5066311500 @default.
• W2285667067 hasAuthorship W2285667067A5069165102 @default.
• W2285667067 hasAuthorship W2285667067A5075841774 @default.
• W2285667067 hasAuthorship W2285667067A5090987336 @default.
• W2285667067 hasBestOaLocation W22856670671 @default.
• W2285667067 hasConcept C104317684 @default.
• W2285667067 hasConcept C114851261 @default.
• W2285667067 hasConcept C121608353 @default.
• W2285667067 hasConcept C126322002 @default.
• W2285667067 hasConcept C143998085 @default.
• W2285667067 hasConcept C145059251 @default.
• W2285667067 hasConcept C2780427987 @default.
• W2285667067 hasConcept C3019054536 @default.
• W2285667067 hasConcept C502942594 @default.
• W2285667067 hasConcept C55493867 @default.
• W2285667067 hasConcept C71924100 @default.
• W2285667067 hasConcept C86803240 @default.

• next